Manufacturing and regulatory hurdles threaten cell and gene therapy progress

Summary

The article discusses how manufacturing and regulatory challenges are hindering the progress of cell and gene therapies, particularly in cancer treatment. It argues that until these risks become easier to underwrite, investment capital will continue to drift away from these promising technologies, delaying potentially life-saving treatments. The piece also touches on the inadequacy of reactive vulnerability management in cybersecurity, noting that the old model of patching no longer works given the current volume of CVEs and faster exploit timelines.

Source

bskyManufacturing and regulatory hurdles threaten cell and gene therapy progressmedium.com